| ²é¿´: 354 | »Ø¸´: 1 | ||
| ¡¾½±Àø¡¿ ±¾Ìû±»ÆÀ¼Û1´Î£¬×÷ÕßfishhopeÔö¼Ó½ð±Ò 0.8 ¸ö | ||
[×ÊÔ´]
¡¶»¯Ñ§Ç°ÑØ¡·2011Äê11Ô£¨Ó¢Îİ棩£Thomson Reuters
|
||
|
IN THIS ISSUE The nutlins were first identified by scientists screening a chemical library at Hoffmann-La Roche. In this article, we showcase a new synthetic route to (-)-nutlin 3 recently developed by Tyler Davis and Jeffrey Johnston of Vanderbilt University, that paves the way into the enantioselective arena of nutlin synthesis. A wide range of new skeletons emphasize that novel chemical scaffolds with biological activity underpin major advances in medicinal chemistry. New molecular mechanisms of action are disclosed for a variety of indications. This issue includes drugs related to diabetes, cancer and other conditions such as Graves¡¯ disease and multiple sclerosis. In this report, we look at how the downsizing pharmaceutical industry is generating new opportunities for the smaller biotechnology and discovery companies. Collaborations between large pharma companies and these smaller enterprises, and even university departments and their spin-off companies, can help cut the overall risk exposure as well as lower investment costs significantly through a focus on developing only those drugs emerging from small laboratories that already show a great deal of clinical promise. Further to this article, Thomson Reuters has produced a report commemorating the 2011 International Year of Chemistry, titled ¡°The Changing Role of Chemistry in Drug Discovery¡±. The report explores the themes of this article in greater depth, with the input from many key pharmaceutical industry players, and examines how life in drug discovery has changed and how it will continue to change and adapt in the future. |
» ±¾Ìû¸½¼þ×ÊÔ´Áбí
-
»¶Ó¼à¶½ºÍ·´À¡£ºÐ¡Ä¾³æ½öÌṩ½»Á÷ƽ̨£¬²»¶Ô¸ÃÄÚÈݸºÔð¡£
±¾ÄÚÈÝÓÉÓû§×ÔÖ÷·¢²¼£¬Èç¹ûÆäÄÚÈÝÉæ¼°µ½ÖªÊ¶²úȨÎÊÌ⣬ÆäÔðÈÎÔÚÓÚÓû§±¾ÈË£¬Èç¶Ô°æÈ¨ÓÐÒìÒ飬ÇëÁªÏµÓÊÏ䣺xiaomuchong@tal.com - ¸½¼þ 1 : cutting_edge_of_chemistry_Nov2011.pdf
2014-02-27 09:31:25, 472.51 K
» ²ÂÄãϲ»¶
Ò»Ö¾Ô¸ÌìÖÐÒ½ÖÐҩѧר˶£¬Ï£ÍûÓÐbÇøµÄÀÏʦ¿ÉÒÔ¿¼ÂÇÒ»ÏÂÎÒ
ÒѾÓÐ1È˻ظ´
µ÷¼Á
ÒѾÓÐ3È˻ظ´
Ò©ÎïѧÂÛÎÄÈóÉ«/·ÒëÔõôÊÕ·Ñ?
ÒѾÓÐ122È˻ظ´
ҩѧѧ˶326Çóµ÷¼Á
ÒѾÓÐ0È˻ظ´
26Ä격ʿÉêÇë
ÒѾÓÐ20È˻ظ´
Ò©Àíѧ¡¢ÁÙ´²Ò©Ñ§·½Ïò µ÷¼Á
ÒѾÓÐ1È˻ظ´
ÇóÖú ±½Á×Áò°·JP
ÒѾÓÐ0È˻ظ´
100½ð±Ò °¢ÄªÎ÷ÁÖ¿ËÀάËá¼ØÆ¬BPÒ©µäÖÐÌáµ½µÄ¿ËÀάËá¾ÛºÏÎï¾ßÌå½á¹¹Ê½ÊÇɶ£¿
ÒѾÓÐ2È˻ظ´
ÉÅʳ²¹³ä¼ÁºÏ¹æÐÔ½»Á÷
ÒѾÓÐ0È˻ظ´
Ò»Ö¾Ô¸Õã´óҩѧÇóµ÷¼Á
ÒѾÓÐ0È˻ظ´
¸ßθßѹ·´Ó¦ÇóÖú
ÒѾÓÐ4È˻ظ´
» ±¾Ö÷ÌâÏà¹Ø¼ÛÖµÌùÍÆ¼ö£¬¶ÔÄúͬÑùÓаïÖú:
¡¾Èí¼þ¡¿Thomson Reuters EndNote X7 for Mac
ÒѾÓÐ139È˻ظ´
¡¾Èí¼þ¡¿Thomson Reuters EndNote X7 17.0.2.7390 ²Î¿¼ÎÄÏ×¹ÜÀíÈí¼þ
ÒѾÓÐ306È˻ظ´
2013µÚÈý¼¾¶Èҩҵй۲죨Thomson Reuters£©ÒÔ¼°2013Äê1-3¼¾¶ÈµÄ·ÂÖÆÒ©·¢Õ¹¶¯Ì¬
ÒѾÓÐ72È˻ظ´
ÇëÎÊthomson reuters ºÍSCIµ½µ×ʲô¹ØÏµ£¿Õâ¸öÔÓÖ¾±»SCIÊÕ¼ÁËÂð£¿
ÒѾÓÐ9È˻ظ´
*** journal have been tracked for Impact Factors by Thomson Reuters(ISI)
ÒѾÓÐ7È˻ظ´
¹ØÓÚSensor Letters
ÒѾÓÐ6È˻ظ´
¼òµ¥»Ø¸´
ald2Â¥
2014-04-22 22:42
»Ø¸´
ÎåÐÇºÃÆÀ ¶¥Ò»Ï£¬¸Ðл·ÖÏí£¡














»Ø¸´´ËÂ¥